Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Tonsillar Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × motexafin gadolinium × Clear all
NCT00129844 2008-08-20

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Completed
108 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡